Pinnacle Lab Solutions

12/23/2025

The FDA has approved Bristol Myers Squibb Breyanzi® (lisocabtagene maraleucel) for adult patients with relapsed or refractory marginal zone lymphoma (MZL), making it the first CAR T cell therapy approved for this indication. For patients with limited options, this represents a meaningful expansion of access to advanced cell therapy.

This approval lands close to home for our team. Earlier this year, Thalia Taylor, founder of Pinnacle Lab Solutions, lost her only aunt to a blood cancer. Experiencing a diagnosis like that within your own family changes how announcements like this are received. The science stops being abstract.

Innovations like this are part of what motivates Pinnacle’s work in bringing the lab closer to the patient. Translating complex science into reliable, compliant, and accessible clinical testing is not just a technical exercise. It is how discoveries move from development into real clinical impact.

Pinnacle Lab Solutions has been proud to support Bristol Myers Squibb as a consulting partner for three of the last four years. Working alongside BMS teams has provided a close view of the rigor required across development, clinical operations, and regulatory ex*****on to make therapies like this possible. Each approval reflects years of coordinated effort with patient safety and outcomes at the center.

This moment represents real progress for patients with rare blood cancers and for the clinicians caring for them. It is a reminder that innovation matters most when it reaches patients.
hashtag


hashtag ://www.europeanpharmaceuticalreview.com/news/268632/bristol-myers-squibb-wins-fifth-us-approval-for-car-t-cell-therapy-breyanzi/

The FDA’s latest authorisation makes it the most widely approved of any CD19-directed CAR T therapy in cancer.

12/05/2025

I am excited to share that I attended my first official meeting as a member of the Columbia University Center for Radiological Research Advisory Council.

For more than a century, the CRR has trained leaders who have shaped how radiation is used in medicine, energy, safety, and public health. Their work has optimized the safest use of imaging, improved radiation therapy for cancer, guided national responses to radiological emergencies, and provided balanced, science based insight into the use of nuclear power. These contributions influence everyday life in profound ways, from individual patient care to global policy decisions.

This mission resonates deeply with my passion for bringing healthcare innovation, wellness, and evidence based communication into the public sphere. I am also passionate about expanding the innovation and awareness of Far-UVC, a brilliant discovery from David Brenner and his team at the CRR. Far-UVC offers promising new pathways for supporting public health through safe and scientifically grounded approaches to air and surface disinfection. Translating advanced research into practical, real world benefit to expand patient care has been at the center of my work for many years, and I am grateful for the opportunity to continue that commitment through this role.

In a world where science, health, and public perception are tightly connected, organizations like the CRR play a crucial role in helping society understand complex topics rather than fear them. I am honored to contribute to that work and to support ongoing efforts to train the next generation of radiation scientists, strengthen education pipelines, and advance research that serves both human health and the public good.

Grateful for the warm welcome and energized for what lies ahead.

05/26/2025

🔬 Promising advancement in Alzheimer’s diagnostics:
New findings show that a blood test can reliably predict the presence or absence of amyloid pathology — a hallmark of Alzheimer’s — at the time of testing in cognitively impaired patients.

🧠 Designed for use in specialized care settings, this test could become a powerful tool for clinicians evaluating patients with signs of cognitive decline.

📌 As always, results should be interpreted alongside comprehensive clinical information.

The U.S. Food and Drug Administration cleared for marketing the first in vitro diagnostic device that tests blood, to aid in diagnosing Alzheimer’s disease.

05/16/2025

ACOG’s new guidelines are a vital step toward more compassionate, patient-centered care. By standardizing conversations around pain management, more patients will be heard, supported—and spared unnecessary suffering during essential gynecological procedures. 💜

Read more via :

The new guidelines urge doctors to "not underestimate the pain experienced by patients."

10/07/2024

This year’s Nobel Prize in Medicine has been awarded to
Victor Ambros and Gary Ruvkun for their of . Their research unveiled a fundamental principle of gene regulation, shedding light on how gene activity is controlled at the level. This discovery not only deepens our understanding of biology but also holds potential for new therapeutic approaches in medicine.
Congratulations to both for this remarkable achievement, which will continue to inspire innovation and progress in the scientific community!

https://www.npr.org/2024/10/07/g-s1-26653/nobel-prize-in-medicine-honors-two-americans-for-discovery-of-microrna🎉🎉🎉🎉🎉🎉🎉🎉🎊🍾🍾🎉

The Nobel Assembly said that their discovery is "proving to be fundamentally important for how organisms develop and function."

03/12/2024

Exciting visit today Columbia University Vanderbilt Dental Clinic! I attended an exclusive tour showcasing their use of to ensure against airborne viruses like and -19. With FAR UVC fixtures strategically placed throughout the clinic, they're setting a new standard for safe dental care. Kudos to their team for prioritizing patient well-being! #222